Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Phase I–II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology(2024)10.1007/s00280-024-04714-zSource: DataRank Database

Phase I–II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors is a research paper published in Cancer Chemotherapy and Pharmacology (2024). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.51)OA: hybridTopics (59)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Axel Grothey ORCID,Darren Sigal ORCID,Heinz-Josef Lenz,Howard S. Höchster ORCID,Yee Chao ORCID

Live enrichment

PubMed:39311947 PMC:PMC11573804 OpenAlex:https://openalex.org/W4402733219

NIH National Cancer Institute

Grant: P30 CA016672

National Institutes of Health

Grant: 3P30CA016672-41S4

Cancer Center Support (CORE) Grant

OBI Pharma, Inc.

FWCI

0.51

Citation Percentile

0.6%

Citation Trend

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://link.springer.com/content/pdf/10.1007/s00280-024-04714-z.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s00280-024-04714-z.pdf

publisherhttps://link.springer.com/article/10.1007/s00280-024-04714-z/fulltext.html

journalhttps://doi.org/10.1007/s00280-024-04714-z

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39311947

Fields of Study

Monoclonal and Polyclonal Antibodies ResearchGlycosylation and Glycoproteins ResearchToxin Mechanisms and Immunotoxins03 medical and health sciences0302 clinical medicineHumansMaleFemaleMiddle AgedNeoplasmsAgedAntibodies, Monoclonal, HumanizedAdultAntigens, Tumor-Associated, CarbohydrateDose-Response Relationship, DrugAged, 80 and overImmunoglobulin GMaximum Tolerated Dose

MeSH Terms

AdultAgedAged, 80 and overDose-Response Relationship, DrugFemaleHumansImmunoglobulin GMaleMiddle AgedNeoplasmsAntigens, Tumor-Associated, CarbohydrateMaximum Tolerated DoseAntibodies, Monoclonal, Humanized

Keywords

Monoclonal antibodyAntigenAntibodyMedicineSolid tumorTumor associated antigenImmunologyCancer researchInternal medicineCancerAdvanced cancerGlobo HIgg1 AntibodyObi-888MaleAdultAged, 80 and overDose-Response Relationship, DrugMaximum Tolerated DoseMiddle AgedAntibodies, Monoclonal, HumanizedNeoplasmsImmunoglobulin GHumansOriginal ArticleFemaleAntigens, Tumor-Associated, CarbohydrateAged

Sustainable Development Goals

SDG 0: Good health and well-being

Phase I–II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors

FAIR Checklist

Authors (10)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)